Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES. NAME: Jennifer L. Hall, Ph.D. eRA COMMONS USER NAME (credential, e.g., agency login): Jlhall POSITION TITLE: Chief EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.) INSTITUTION AND LOCATION South Dakota State University, Brookings University of Wisconsin, Madison University of California, Berkeley Stanford University, Stanford Brigham and Women’s Hospital, Harvard Medical School, Boston DEGREE (if applicable) BS MS PhD Post-doc Post-doc Completion Date MM/YYYY 1986-90 1990-92 1993-95 1995-96 1996-99 FIELD OF STUDY Biology/Biochemistry Human Biodynamics Biodynamics/Physiology Molecular Biology Molecular Biology A. Personal Statement I lead the American Heart Association Institute for Precision Cardiovascular Medicine. This role provides an opportunity to establish new strategies for research linked with the latest technical advances to maintain our goal of patient engagement. We reach over 32 million United States citizens each year through our multiple engagement circles in our Heart Walks, Go Red for Women, and Patient Support Networks. At the Institute, we are establishing the technology and finding the brightest minds from multiple different disciplines to educate and engage with these 32 million individuals and beyond in new ways that excite and maintain relationships to build better physical and mental health across the United States and eventually the globe. Non-communicable diseases are rapidly advancing to make up a majority of deaths globally. The AHA is partnering with the United Nations and other strategic partners to take on this challenge. The Institute for Precision Cardiovascular Medicine is at the forefront and we will continue to forge new partnerships to take on these challenges, and build on the expertise and scientific foundation of our 31,000 scientists and clinicians. B. Positions and Honors Academic Positions 1999–01 Assistant Professor of Biochemistry, Cardiovascular Research Institute, Morehouse School of Medicine 2001–07 Assistant Professor, Department of Medicine, University of Minnesota, 2002–16 Director, Program in Translational Genomics, Lillehei Heart Institute, University of Minnesota, 2006-10 Visiting Professor, Broad Institute of MIT and Harvard, 2008– Associate Professor, Department of Medicine, University of Minnesota 2010-15 Visiting Professor, University of Virginia 2016Chief, AHA Institute for Precision Cardiovascular Medicine, American Heart Association Honors 2008-15 2009-16 2009-11 2010 2011-12 Vice-President, International Society of Cardiovascular Translational Research Associate Editor, Journal of American College of Cardiology Co-Chair, AHA, Genomics and Observational Epidemiology Study Section Chair, Genome Canada, Grant Study Section National Planning Committee, American Heart Association 2011-16 2011-12 2013-16 2012-13 2010-16 2012-13 2014-16 2014 2014-16 2015 NHLBI PPG Grant Study Section Chair, Professional Education and Publications, FGTB Council, AHA Editor in Chief, Journal of Cardiovascular Translational Research Vice-chair, FGTB Council, AHA DNA Framingham Advisory Committee Chair, AHA Genomics and Observational Epidemiology Study Section Chair, FGTB Council, AHA Chair, AHA Prevention Network Grant Study Section Chair, AHA Oversight Committee, Prevention Network AHA Collaborative Science Award Grant Committee. C. Contributions to Science 1. Vascular Smooth Muscle Cell Behavior and the Impact on Vessel Phenotype and Function. We have defined the genes and regulatory pathways that determine the regulation of vascular cell behavior and how this regulates vessel phenotype and function. a. Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat. Med. 1988; 4(2): 222-7. PMID: 9461197. b. Adhikari N, Basi D, Carlson M, Mariash A, Hong A, Lehman U, Mullegama S, Weir E, Hall JL. Tissue specific increase in GLUT1 in Smooth Muscle Decreases Vascular Contractility and Increases Inflammation in response to Vascular Injury. ATVB 31(1):86-94, 2011. PMCID: PMC3014530 c. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL. A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ. Res. 2002; 90(3):340-7. PMID 11861424. d. Adhikari N, Billaud M, Carlson M, Lake SP, Montaniel KR, Staggs R, Guan W, Walek D, Desir S, Isakson BE Barocas VH and Hall JL. Vascular biomechanical properties in mice with smooth muscle specific deletion of Ndst1. Mol. Cell. Biochem. 385(102):225-38, 2014. PMID 24101444. e. Adhikari N, Shekar KC, Staggs R, Win Z, Steucke K, Lin YW, Wei LN, Alford P, Hall JL. Guidelines for the isolation and characterization of murine vascular smooth muscle cells. J. Cardiovasc. Transl. Res. 2015:8(3):158-63. PMID: 25788147. 2. Combining genomic approaches and human genetic data with mechanistic regulation to identify how genes and pathways lead to disease continues to be a long-standing interest. a. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV, Li X, Li H, Kuperwasser N, Ruda VM, Pirruccello JP, Muchmore B, Prokunina-Olsson L, Hall JL, Schadt EE, Morales CR, Lund-Katz S, Phillips MC, Wong J, Cantley W, Ejebe KG, Orho-Melander M, Melander O, Koteliansky V, Krauss R, Cowan CA, Kathiresan S, Rader DJ. From genotype to phenotype at the 1p13 cholesterol and heart attack locus. Nature 466:714-719, 2010. PMID:20686566. PMCID: PMC3062476. b. Prokunina-Olsson L, Welch C, Hansson O, Adhikari N, Scott LJ, Usher N, Tong M, Sprau A, Swift A, Bonnycastle LL, Erdos MR, He Z, Saxena R, Harmon B, Kotova O, Hoffman EP, Altshuler D, Groop L, Boehnke M, Collins FS, Hall JL. Tissue-specific alternative splicing of TCF7L2. Hum. Mol. Genet. 18:3795804, 2009.PMID: 19602480 c. Hall JL, Birks EJ, Rider J, Grindle S, Barton P, Mariash A, Charles N, Dyke DB, Pagoni F, Yacoub MH. Miller LW. Molecular signature of recovery following left ventricular assist device (LVAD) support. Eur Heart J. 28:613-27, 2007. PMID: 17132651. d. Mitchell A, Guan W, Staggs R, Hamel A, Hozayen S, Adhikari N, Grindle S, Desir S, John R, Hall JL*, Eckman P*. Identification of differentially expressed transcripts and pathways in blood one week and six months following implant of left ventricular assist devices. PLOS ONE. 8(10):e77951, 2013. PMID 24205042 Complete List of Published Work in MyBibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/1LolccRSJ3JQB/bibliograpahy/40349441/public/?sort=date&direction=descending D. Research Support Current Research Support Funding Institution: National Science Foundation Grant Title: “Empirically Determined Growth Laws for Vascular Smooth Muscle Cell Mechano-Adaptation” PI: Alford Co-I: Hall Project Dates: 8/1/2016-7/31/2019 Total Project Cost: $366,742 Funding Institution: Grant Title: Project Goal: PI: Project Dates: Total Project Cost: Private foundation, Lindahl Grant “A Porcine Transgenic Model of BAV” To establish a porcine transgenic model of bicuspid aortic valve. Hall 5/1/2014-4/31/2016* $250,000 Funding Institution: Grant Title: Project Goal: PI: Project Dates: Total Project Cost NIH-1 R21 HL104596-01 Genetic Risk Factors of Myocyte Contractility in Human Heart Failure To identify SNPs in miRNA binding sites associated with Contractility Hall No cost extension through 4/30/14 $420,853 Funding Institution: Grant Title: Project Goal: NIH-R01HL081715A1 “The role of heparan sulfate in vascular remodeling.” The goal of this project is to determine how heparan sulfate fine structure affects the process of vascular remodeling in response to injury. Hall 05/01/07-04/30/12 (no cost extension through 4/30/13) $1,860,097 PI: Project Dates: Total project cost: Funding Institution: Grant Title: Project Goal: PI: Project Dates: Total project cost: Funding Institution: Grant Title: Project Goal: PI: Juvenile Diabetes Research Foundation: 1-2007-819 “Defining the role of glucose in vascular remodeling.” The goal of this project is to establish how increased glucose uptake in smooth muscle affects vascular structure, inflammation, and remodeling. Hall 09/01/07-08/31/10 $420,595 NIH 1R21DK078029-01A1 “Defining how a variant in TCF7L2 confers increased risk for type 2 diabetes.” The goal of this project is to identify the biological function of a variant in TCF7L2 that confers increased risk for type 2 diabetes. Jennifer Hall Project Date: Total project cost: 09/21/07-08/31/10 $406,640